Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17120856 | PRODUCT | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 16972008 | LOW GLYCEMIC COMPOSITION AND METHODS OF MAKING AND USING THEREOF | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17059428 | MILD COMPOSITION FOR USE IN TOPICAL TREATMENT OF SKIN AND NAIL DISORDERS CAUSED BY VIRUS AND FUNGUS | November 2020 | April 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17084514 | PHARMACEUTICAL OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF | October 2020 | July 2022 | Allow | 21 | 1 | 0 | No | No |
| 17083232 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF | October 2020 | October 2022 | Allow | 23 | 0 | 0 | No | No |
| 17077969 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | October 2020 | January 2025 | Abandon | 51 | 8 | 0 | Yes | No |
| 17077897 | OXYGENATED SKIN LOTION | October 2020 | October 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17070365 | ANTIMICROBIAL COMBINATIONS SYSTEM AND METHOD | October 2020 | December 2023 | Abandon | 38 | 2 | 1 | No | No |
| 17067676 | ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17067259 | TOPICAL FORMULATIONS COMPRISING STRONTIUM AND METHYLSULFONYLMETHANE (MSM) AND METHODS OF TREATMENT | October 2020 | October 2023 | Allow | 36 | 3 | 1 | Yes | No |
| 17060121 | Antibacterial and Non-Clumping Liquid Spray | October 2020 | January 2023 | Abandon | 27 | 2 | 0 | No | No |
| 17042473 | ANTIPERSPIRANT PRODUCTS | September 2020 | February 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17033294 | TREATMENT AND PROPHYLAXIS OF RADIATION DERMATITIS | September 2020 | August 2023 | Allow | 35 | 1 | 0 | Yes | No |
| 17040825 | SOLUTIONS COMPRISING OZONIZED OIL | September 2020 | November 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16977048 | COMPOSITE PARTICLES | August 2020 | October 2024 | Abandon | 49 | 1 | 1 | No | No |
| 17001726 | Slow Release Calcium Composition | August 2020 | July 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 16991397 | Praziquantel Formulations | August 2020 | March 2022 | Abandon | 19 | 3 | 1 | No | No |
| 16988387 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | August 2020 | February 2025 | Abandon | 54 | 5 | 0 | No | No |
| 16941400 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | July 2020 | September 2020 | Allow | 2 | 0 | 0 | Yes | No |
| 16941414 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | July 2020 | September 2020 | Allow | 2 | 0 | 0 | Yes | No |
| 16929140 | NUTRITIONAL SUPPLEMENT FOR GROWTH ENHANCEMENT | July 2020 | February 2021 | Allow | 7 | 1 | 0 | No | No |
| 16927613 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COVID-19 | July 2020 | July 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16916713 | COMPOSITION AND PROCESS FOR REMOVING MILDEW AND FUNGAL GROWTH | June 2020 | July 2021 | Abandon | 12 | 2 | 0 | No | No |
| 16912734 | METHOD FOR DISINFECTION OF ITEMS AND SPACES | June 2020 | May 2022 | Allow | 22 | 4 | 0 | Yes | No |
| 16772788 | FILM FORMULATION COMPRISING VARDENAFIL, METHOD FOR ITS PREPARATION, AND USE THEREOF | June 2020 | August 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16772481 | AN ANTIMICROBIAL COMPOSITION | June 2020 | November 2023 | Abandon | 41 | 1 | 0 | No | No |
| 16900507 | COMPOSITIONS AND METHODS FOR TREATING WOUNDS | June 2020 | October 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16771779 | PHARMACEUTICAL COMPOSITION COMPRISING A COLLOIDAL DISPERSION AND A THERAPEUTIC AGENT AND METHODS AND USES THEREOF | June 2020 | July 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16898990 | MATERIAL TO FORM A HYDROGEL | June 2020 | March 2021 | Allow | 9 | 0 | 0 | No | No |
| 16769843 | AN ANTIMICROBIAL COMPOSITION | June 2020 | May 2024 | Abandon | 47 | 5 | 1 | No | No |
| 16892382 | Antibacterial and Non-Clumping Liquid Spray | June 2020 | June 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16769682 | FAST-ACTING BIOCIDAL CLEANSING COMPOSITION | June 2020 | April 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16892421 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | June 2020 | November 2020 | Allow | 5 | 1 | 0 | No | No |
| 15931797 | Antibacterial and Non-Clumping Liquid Spray | May 2020 | September 2021 | Abandon | 16 | 2 | 0 | No | No |
| 16872554 | ANTIBACTERIAL MATERIAL AND ANTIBACTERIAL FILM AND ANTIBACTERIAL MEMBER USING THE SAME | May 2020 | October 2023 | Allow | 41 | 1 | 0 | Yes | No |
| 16869199 | METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEX | May 2020 | September 2023 | Allow | 41 | 2 | 0 | Yes | No |
| 16859609 | Magic Skin Repair Serum | April 2020 | July 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16855717 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | April 2020 | September 2022 | Allow | 29 | 4 | 0 | No | No |
| 16830539 | C3-C5 N-Alkyl-Gamma-Butyrolactam-Containing Antimicrobial Compositions and Uses Thereof | March 2020 | June 2021 | Allow | 15 | 2 | 1 | Yes | No |
| 16827940 | WOUND HEALING TOPICAL FORMULATION AND PREPARATION THEREOF | March 2020 | January 2022 | Abandon | 21 | 1 | 1 | No | No |
| 16818488 | Compositions and Methods for Inhibiting Endospores Using Green Tea Polyphenols | March 2020 | February 2024 | Abandon | 47 | 4 | 1 | Yes | No |
| 16795779 | METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES | February 2020 | April 2023 | Allow | 37 | 3 | 1 | Yes | Yes |
| 16745712 | Antibacterial and Non-Clumping Liquid Spray | January 2020 | January 2023 | Abandon | 36 | 3 | 0 | No | No |
| 16735209 | COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAIN | January 2020 | February 2023 | Allow | 37 | 4 | 0 | Yes | No |
| 16721872 | COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERS | December 2019 | March 2024 | Abandon | 51 | 4 | 1 | Yes | No |
| 16621764 | MICROBICIDAL COMPOSITION | December 2019 | January 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16676325 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | November 2019 | March 2020 | Allow | 4 | 1 | 0 | Yes | No |
| 16609839 | BACTERICIDE COMPOSITION | October 2019 | May 2023 | Abandon | 43 | 4 | 1 | Yes | No |
| 16665473 | ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE | October 2019 | January 2021 | Abandon | 15 | 1 | 0 | No | No |
| 16497694 | ANTIBACTERIAL BIOLOGICAL IMPLANT | September 2019 | January 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16576301 | ANTICOAGULATION FLUID COMPRISING CITRATE AND PHOSPHATE | September 2019 | April 2021 | Allow | 19 | 3 | 0 | Yes | No |
| 16495159 | ODOR CONTROL AGENT | September 2019 | November 2021 | Abandon | 26 | 2 | 0 | No | No |
| 16494789 | Treatment of herpes simplex symptoms on skin and mucous membrane of mammals | September 2019 | May 2022 | Abandon | 32 | 2 | 1 | No | No |
| 16492999 | HAIR CARE COMPOSITION | September 2019 | September 2021 | Allow | 25 | 2 | 1 | Yes | No |
| 16567660 | TOPICAL ANTISEPTIC SYSTEM | September 2019 | December 2021 | Allow | 28 | 3 | 1 | Yes | No |
| 16483889 | COMPOSITION COMPRISING IMMEDIATE RELEASE AND EXTENDED RELEASE CAPECITABINE | August 2019 | July 2020 | Abandon | 11 | 0 | 1 | No | No |
| 16522259 | ENHANCED ANTIBIOTIC AND DRUG DELIVERY FOR AQUEOUS TOPICAL APPLICATIONS FOR HUMAN AND VETERINARY USES | July 2019 | April 2023 | Abandon | 44 | 5 | 1 | Yes | No |
| 16515390 | Slow Release Calcium Composition | July 2019 | January 2021 | Abandon | 18 | 2 | 1 | No | No |
| 16477889 | STABLE LIQUID COMPOSITION COMPRISING BOTULINUM TOXIN | July 2019 | September 2021 | Allow | 26 | 2 | 1 | No | No |
| 16476019 | ORAL DOSAGE FORM FOR ENHANCED SOLUBILIZATION OF A POORLY SOLUBLE ACTIVE AGENT AND METHOD OF PREPARATION | July 2019 | June 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16473939 | ANHYDROUS COMPOSITION COMPRISING A MAGNESIUM SALT | June 2019 | August 2023 | Allow | 50 | 5 | 1 | Yes | No |
| 16450159 | DEODORANT STICKS | June 2019 | May 2024 | Abandon | 59 | 4 | 1 | Yes | Yes |
| 16470890 | COMPOSITION FOR ALLEVIATING ATOPIC SKIN SYMPTOMS, CONTAINING POLY-GAMMA-GLUTAMIC ACID | June 2019 | November 2021 | Abandon | 29 | 3 | 0 | No | No |
| 16444473 | COMPOSITION AND PROCESS FOR REMOVING MILDEW AND FUNGAL GROWTH | June 2019 | October 2020 | Abandon | 16 | 2 | 0 | Yes | No |
| 16440855 | CONTAINERS THAT CONTAIN ANIONIC CANNABINOID MOLECULES DISSOLVED IN WATER | June 2019 | March 2020 | Abandon | 9 | 2 | 1 | No | No |
| 16440889 | METHODS OF ADMINISTERING ANIONIC CANNABINOID MOLECULES DISSOLVED IN WATER | June 2019 | August 2020 | Allow | 14 | 2 | 1 | Yes | No |
| 16440878 | METHODS OF PRODUCING ANIONIC CANNABINOID MOLECULES DISSOLVED IN WATER | June 2019 | September 2019 | Allow | 3 | 0 | 0 | Yes | No |
| 16434959 | FORMALDEHYDE-FREE PRESERVATIVES FOR HIGHLY SUSCEPTIBLE PRODUCTS | June 2019 | February 2021 | Abandon | 20 | 2 | 1 | No | No |
| 16428216 | SPORICIDAL METHODS AND COMPOSITIONS | May 2019 | September 2022 | Allow | 40 | 4 | 1 | Yes | No |
| 16462689 | METHOD AND "IDEPS" COMPOSITION FOR DESTROYING MICROORGANISMS IN A SESSILE STATE | May 2019 | April 2021 | Allow | 23 | 1 | 1 | Yes | No |
| 16416689 | COATING FOR MEDICAL EQUIPMENT AND ENDOSCOPE | May 2019 | September 2020 | Abandon | 16 | 2 | 0 | No | No |
| 16416369 | Pharmaceutical Composition of Acetaminophen/Ibuprofen | May 2019 | January 2021 | Abandon | 19 | 2 | 1 | No | No |
| 16462069 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE PERCEPTION OF FECAL MALODOUR | May 2019 | March 2025 | Abandon | 60 | 5 | 1 | No | Yes |
| 16415339 | BOTANICAL FILM-FORMING ACNE COMPOSITIONS | May 2019 | June 2021 | Abandon | 25 | 2 | 1 | No | No |
| 16411801 | SHELLAC AND PACLITAXEL COATED CATHETER BALLOONS | May 2019 | July 2021 | Allow | 26 | 2 | 1 | Yes | No |
| 16349796 | MATERIALS AND METHODS FOR THE CONTROL OF NEMATODES | May 2019 | July 2021 | Allow | 26 | 3 | 1 | Yes | No |
| 16394289 | CAROTENOID-CONTAINING COMPOSITION | April 2019 | August 2020 | Abandon | 16 | 1 | 1 | No | No |
| 16344739 | ENGINEERED BIOCOMPATIBLE ANTIBIOTIC PARTICLES AND THEIR USE AGAINST URINARY TRACT INFECTION | April 2019 | March 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16380186 | Biopharma Application Of Micell Technology | April 2019 | July 2021 | Abandon | 27 | 2 | 1 | No | No |
| 16370319 | SELF-HEALING HYDROGEL AND USE THEREOF | March 2019 | January 2022 | Abandon | 34 | 4 | 1 | No | No |
| 16334976 | ORAL MODIFIED RELEASE FORMULATIONS | March 2019 | January 2021 | Abandon | 22 | 2 | 1 | No | No |
| 16292639 | STERILE INJECTABLE COMPOSITION COMPRISING MELPHALAN | March 2019 | April 2020 | Abandon | 13 | 1 | 0 | No | No |
| 16280112 | Chemical Formulations and Their Use in Neutralizing or Eliminating Odors | February 2019 | June 2021 | Allow | 28 | 2 | 1 | Yes | No |
| 16281026 | CONTROLLED DELIVERY SYSTEM | February 2019 | April 2022 | Abandon | 38 | 2 | 0 | Yes | Yes |
| 16275739 | PHARMACEUTICAL MATRIX FORMULATIONS COMPRISING DIMETHYL FUMARATE | February 2019 | October 2022 | Allow | 44 | 6 | 0 | No | No |
| 16266513 | ABUSE-RESISTANT MUCOADHESIVE DEVICES FOR DELIVERY OF BUPRENORPHINE | February 2019 | February 2020 | Abandon | 12 | 1 | 0 | No | No |
| 16322819 | ZINC OXIDE-CONTAINING COMPOSITE PARTICLES, ULTRAVIOLET-SHIELDING COMPOSITION, AND COSMETIC | February 2019 | March 2021 | Abandon | 26 | 2 | 1 | No | No |
| 16259541 | Drug/polymer Composite Materials And Methods Of Making The Same | January 2019 | September 2021 | Abandon | 32 | 4 | 0 | No | No |
| 16256389 | COMPOSITION FOR PRODUCING HYDROGEN RICH WATER AND OTHER PRODUCTS | January 2019 | January 2022 | Allow | 36 | 4 | 1 | Yes | Yes |
| 16256857 | METHODS AND DRESSINGS FOR SEALING INTERNAL INJURIES | January 2019 | September 2021 | Abandon | 32 | 1 | 1 | No | No |
| 16256565 | COMPOSITIONS AND METHODS FOR MULTIPURPOSE DISINFECTION AND STERILIZATION SOLUTIONS | January 2019 | April 2021 | Abandon | 27 | 3 | 0 | No | No |
| 16254850 | PENFLUFEN AS A WOOD PRESERVATIVE AGAINST WOOD-DESTROYING BASIDIOMYCETES | January 2019 | March 2023 | Allow | 50 | 4 | 0 | No | Yes |
| 16250349 | HEMOSTATIC MATERIAL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | January 2019 | January 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16243842 | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent | January 2019 | September 2021 | Allow | 32 | 4 | 0 | Yes | No |
| 16240249 | FOAMING CREAM EMULSIONS | January 2019 | November 2024 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 16233503 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | December 2018 | January 2020 | Allow | 13 | 1 | 0 | No | No |
| 16229865 | TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTS | December 2018 | March 2022 | Allow | 39 | 5 | 0 | Yes | No |
| 16311944 | COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL USE DISORDER | December 2018 | May 2024 | Abandon | 60 | 4 | 1 | Yes | Yes |
| 16227089 | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE FOR ADMINISTRATION AT A LOW DAILY DOSE | December 2018 | May 2020 | Abandon | 17 | 1 | 0 | No | No |
| 16310423 | A Novel formulation for rapid wound healing and control of infection | December 2018 | January 2024 | Abandon | 60 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALAWADI, SARAH.
With a 10.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ALAWADI, SARAH works in Art Unit 1619 and has examined 644 patent applications in our dataset. With an allowance rate of 36.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner ALAWADI, SARAH's allowance rate of 36.5% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALAWADI, SARAH receive 2.79 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ALAWADI, SARAH is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +42.8% benefit to allowance rate for applications examined by ALAWADI, SARAH. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 11.9% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 18.1% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 45.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 36.0% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 56.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 70.3% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.4% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.